Here in this article, we take a look at two very promising stock: Arena Pharmaceuticals (NASDAQ ARNA) & Bristol-Myers Squibb (NYSE BMY). Arena Pharmaceuticals stock (NASDAQ ARNA) has been slightly lukewarm as off late. But that may change with a relaunch on the horizon. Bristol-Myers Squibb have a lot of projects on the horizon which should see the stock flourish in the coming future.
Shares of Arena have been up slightly in the last few months, after Arena announced that its marketing partner Eisai has completed its planned increase of 200 additional sales reps for the duo’s fat-fighting pill Belviq. This increase is part of a broader relaunch effort of the drug after it has repeatedly posted disappointing prescription and sales numbers, following its initial commercial launch last year.
Bristol-Myers announced recently that its plans on filing a Biologics Licensing Application for its closely watched PD-1 inhibitor called nivolubmab in the third quarter, as a potential treatment for advanced melanoma that has previously been treated with Yervoy or a BRAF inhibitor regimen.. Bristol-Myers is also in the process of completing a rolling submission for the drug as a treatment for non-small cell lung cancer.
Arena Pharmaceuticals & Bristol-Myers Squibb
In its press release, Bristol-Myers proposed the trade name Opdivo, if nivolumab is granted approval. Bristol-Myers is also developing nivolumab as a potential treatment for renal cell carcinoma, head and neck cancer, glioblastoma and non-Hodgkin lymphoma. Shares are presently unchanged in response to this news.
Arena’s renewed marketing efforts are coming at a pivotal time in the company’s life cycle. Put simply, this may be the last major effort to push the drug Eisai as a treatment for chronic obesity, as it stands. If this effort fails to dramatically improve the drug’s commercial performance, the companies will wait for a label expansion to be approved before using any more resources to try to increase sales.
Arena Pharmaceuticals & Bristol-Myers Squibb News Video
Watch this video for more “Arena Pharmaceuticals & Bristol-Myers Squibb” news.
Arena Pharmaceuticals & Bristol-Myers Squibb Financial News
Despite renewed marketing efforts and a possible relaunch, Arena Pharmaceuticals may find it hard to start a bullish run. Bristol-Myers Squibb have on the other hand, shown all the sign of a good run. Whether it actually happens remains to be seen.
Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.